Citations

Showing 10 of 108135 citations.

Identifying Familial Hypercholesterolemia Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors
Jackson, Candace L. , Keeton, James Z., Eason, Stephen , Ahmad, Zahid , Ayers, Colby , Gore, M. Odette , Sayers, Merlyn , McGuire, Darren K. , Khera, Amit

Mayo Clinic

JAMA Cardiology | May 22, 2019 | Volume: 4 | Issue: 7 | Pages: 685

10.1001/jamacardio.2019.1518 | PMID 31116347 Get It

Sudden Cardiac Death Risk in Hypertrophic Cardiomyopathy
Ommen, Steve R.

Mayo Clinic

JAMA Cardiology | May 22, 2019 | Volume: 4 | Issue: 7 | Pages: 657

10.1001/jamacardio.2019.1438 | PMID 31116363 Get It

Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer
Mason, Brandon R. , Eastham, James A., Mynderse, Lance A. , Pugh, Thomas J., Lee, Richard J. , Davis, Brian J. , Ippolito, Joseph E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 506-513

10.6004/jnccn.2019.7306 | PMID 31085758 Get It

Prostate cancer (PCa) represents a significant source of morbidity and mortality for men in the United States, with approximately 1 in 9 being diagnosed with PCa in their lifetime. The role of imaging in the evaluation of men with PCa has evolved and currently plays a central role in diagnosis, treatment planning, and evaluation of recurrence. Appropriate use of multiparametric MRI (mpMRI) and MRI-guided transrectal ultrasound (MR-TRUS) biopsy increases the detection of clinically significant PCa while decreasing the detection of clinically insignificant PCa. This process may help patients with clinically insignificant PCa avoid the adverse effects of unnecessary therapy. In the setting of a known PCa, patients with low-grade disease can be observed using active surveillance, which often includes a combination of prostate-specific antigen (PSA) testing, serial mpMRI, and, if indicated, follow-up systematic and targeted TRUS-guided tissue sampling. mpMRI can provide important information in the posttreatment setting, but PET/CT is creating a paradigm shift in imaging standards for patients with locally recurrent and metastatic PCa. This article examines the strengths and limitations of mpMRI for initial PCa diagnosis, active surveillance, recurrent disease evaluation, and image-guided biopsies, and the use of PET/CT imaging in men with recurrent PCa. The goal of this review is to provide a rational basis for current NCCN Clinical Practice Guidelines in Oncology for PCa as they pertain to the use of these advanced imaging modalities.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, James L. , Antonarakis, Emmanuel S. , Armstrong, Andrew J. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, James A., Enke, Charles A. , Farrington, Thomas A., Higano, Celestia S. , Horwitz, Eric M. , Kuettel, Michael, McKenney, Jesse K. , Netto, George J. , Penson, David F. , Pow‐Sang, Julio M. , Pugh, Thomas J., Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Schaeffer, Edward M. , Shabsigh, Ahmad , Spratt, Daniel E. , Srinivas, Sandy, Tward, Jonathan D. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Antonarakis, Emmanuel S , Armstrong, Andrew J , Antonarakis, Emmanuel S , Hurwitz, Michael E. , Ippolito, Joseph E. , Kane, Christopher J. , Lang, Joshua M. , Plimack, Elizabeth R. , Small, Eric J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 479-505

10.6004/jnccn.2019.0023 | PMID 31085757 Get It

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019
Brown, Patrick A. , Wieduwilt, Matthew J. , Wang, Eunice S. , Fathi, Amir T. , Litzow, Mark R. , Aoun, Patricia, Bhatnagar, Bhavana , Boyer, Michael W., Bryan, Teresa , Burke, Patrick W. , Coccia, Peter F., Coutré, Steven , Kirby, Suzanne, Massaro, Stephanie, Mattison, Ryan J. , Oluwole, Olalekan O. , Papadantonakis, Nikolaos , Park, Jae H. , Uy, Geoffrey L. , Gregory, Kristina M., Ogba, Ndiya , Wang, Eunice S. , Oluwole, Olalekan O , Uy, Geoffrey , Logan, Aaron C , DeAngelo, Daniel J. , Cassaday, Ryan D. , Advani, Anjali S. , Jain, Nitin , Liu, Arthur , Rubnitz, Jeffrey E. , Shah, Bijal

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 414-423

10.6004/jnccn.2019.0024 | PMID 31085755 Get It

Survival outcomes for older adults with acute lymphoblastic leukemia (ALL) are poor and optimal management is challenging due to higher-risk leukemia genetics, comorbidities, and lower tolerance to intensive therapy. A critical understanding of these factors guides the selection of frontline therapies and subsequent treatment strategies. In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
Augmented intelligence improves stroke risk prediction in atrial fibrillation
Deshmukh, Abhishek , Deshmukh, Abhishek J , DeSimone, Christopher V.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | May 22, 2019 | Volume: 30 | Issue: 9 | Pages: 1462-1463

10.1111/jce.13997 | PMID 31115948 Get It

Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality
Hazeldine, Jon , Hampson, Peter , Lord, Janet M. , Arlt, Wiebke , Arlt, Wiebke , Bancos, Irina , Chortis, Vasileios , Hampson, Peter, Taylor, Angela E.

Mayo Clinic

European Journal of Endocrinology | May 22, 2019 | Volume: 180 | Issue: 6 | Pages: X5

10.1530/eje-16-0969e Get It

Small Interfering RNA Screening for the Small GTPase Rab Proteins Identifies Rab5B as a Major Regulator of Hepatitis B Virus Production
Inoue, Jun , Ninomiya, Masashi , Umetsu, Teruyuki, Nakamura, Takuya , Kogure, Takayuki , Kakazu, Eiji , Iwata, Tomoaki, Takai, Satoshi, Sano, Akitoshi , Fukuda, Mitsunori , Watashi, Koichi , Isogawa, Masanori , Tanaka, Yasuhito , Shimosegawa, Tooru , McNiven, Mark A. , Masamune, Atsushi

Mayo Clinic

Journal of Virology | May 22, 2019 | Volume: 93 | Issue: 15 | Pages: No page available

10.1128/jvi.00621-19 | PMID 31118260 Get It

HBV infection is a worldwide health problem, but the mechanisms of how HBV utilizes cellular machinery for its life cycle are poorly understood. In particular, it has been unclear how the viral components and virions are transported among the organelles. The HBV budding site has been reported to be the ER or MVB, but it has not been clearly determined. In this study, siRNA-based screening of Rab proteins using HBV-expressing cells showed that Rab5B, one of the Rab5 isoforms, has important roles in late steps of the HBV life cycle. Although Rab5 is known to work on early endosomes, this study showed that Rab5B plays a role in the transport of LHBs between the ER and MVB. Furthermore, it affects the transcription of LHBs. This is the first report on the mechanisms of HBV envelope protein transport among the organelles, and the results provide important insights into the therapeutic control of HBV infection.
Radial artery access is under‐utilized in women undergoing PCI despite potential benefits: Mayo Clinic PCI Registry
Chester, Rebecca , Mina, Syeda A. , Lewis, Bradley R., Butterfield, Richard , Chester, Rebecca C , Zhang, Nan , Yang, Eric H.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 22, 2019 | Volume: 95 | Issue: 4 | Pages: 675-683

10.1002/ccd.28341 | PMID 31115141 Get It

Abstract Background Women may benefit from radial artery access (RAA) for percutaneous coronary interventions (PCI) due to a higher risk of bleeding compared to men; however, RAA may be underutilized in women. We sought to determine the frequency and predictors of RAA use in patients undergoing PCI. Methods We studied 21,123 (29.0% female) participants in the Mayo Clinic PCI Registry from January 1, 2006–December 31, 2016. Data were analyzed as a cohort and by time tertiles. Frequency of RAA versus femoral access and bleeding events were recorded. Logistic regression was used to identify predictors of RAA. Results In the overall cohort, women compared to men were older (69.6 ± 12.6 vs. 65.6 ± 11.9; p < .001), more likely to present with acute coronary syndrome (82.0% in women vs. 80.0% in men; p = .0008) and had more comorbidities. RAA increased from tertile one (3.5% for women vs. 4.0% for men; p = .3) through tertile three (46.8% for women vs. 50.3% for men; p = .01), but remained lower in women. In multivariable analysis, female sex is associated with 22% less RAA use (OR 0.78, 95% CI 0.72–0.84; p < .0001). Women compared to men experienced more bleeding (6.3 vs. 3.0%; p < .0001) but bleeding was less likely in RAA (OR 0.45, 95% CI 0.36–0.56; p < .0001). Conclusion Women undergoing PCI are less likely to receive RAA compared to men despite having a higher risk of bleeding. This trend persists despite increase in RAA use. Given the potential benefit of RAA in women, sex should be considered in patient selection for RAA.
Biochemical and clinical response after umbilical cord blood transplant in a boy with early childhood‐onset beta‐mannosidosis
Lund, Troy C. , Miller, Weston P. , Eisengart, Julie B. , Simmons, Katrina, Pollard, Laura, Renaud, Deborah L. , Wenger, David A. , Orchard, Paul J. , Patterson, Marc C. , Lund, Troy C , Wegner, Daniel J

Mayo Clinic

Molecular Genetics & Genomic Medicine | May 22, 2019 | Volume: 7 | Issue: 7 | Pages: No page available

10.1002/mgg3.712 | PMID 31115173 Get It

Abstract Background Deficiency in the enzyme β‐mannosidase was described over three decades ago. Although rare in occurrence, the presentation of childhood‐onset β‐mannosidase deficiency consists of hypotonia in the newborn period followed by global development delay, behavior problems, and intellectual disability. No effective pharmacologic treatments have been available. Methods We report 2‐year outcomes following the first umbilical cord blood transplant in a 4‐year‐old boy with early childhood‐onset disease. Results We show restoration of leukocyte β‐mannosidase activity which remained normal at 2 years posttransplant, and a simultaneous increase in plasma β‐mannosidase activity and dramatic decrease in urine‐free oligosaccharides were also observed. MRI of the brain remained stable. Neurocognitive evaluation revealed test point gains, although the magnitude of improvement was less than expected for age, causing lower IQ scores that represent a wider developmental gap between the patient and unaffected peers. Conclusion Our findings suggest that hematopoietic cell transplant can correct the biochemical defect in β‐mannosidosis, although preservation of the neurocognitive trajectory may be a challenge.